home / stock / tryp:cc / tryp:cc news

TRYP:CC News and Press, Tryp Therapeutics Inc. From 08/03/23

Stock Information
Company Name: Tryp Therapeutics Inc.
Stock Symbol: TRYP:CC
Market: CNQC
Website: tryptherapeutics.com
Menu
TRYP:CC TRYP:CC Quote TRYP:CC Short TRYP:CC News TRYP:CC Articles TRYP:CC Message Board
Get TRYP:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
TRYP:CC - Tryp Therapeutics Announces Jason Carroll as New Chief Executive Officer

KELOWNA, BC / ACCESSWIRE / August 3, 2023 / Tryp Therapeutics Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company dedicated to developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, is p...
TRYP:CC - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Reports on the Passing of Director David Tousley

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has announced the passing of one of its directors. The company released a stat...

TRYP:CC - With Great Sadness Tryp Announces the Passing of David Tousley, Director

KELOWNA, BC / ACCESSWIRE / August 2, 2023 / Tryp Therapeutics, Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), announces with deep regret the passing of Mr. David Tousley, Director of Tryp and Chair of Tryp's Audit Committee. Dave was a highly experienced director who provided the Boar...

TRYP:CC - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Proceed with Phase 2A Clinical Trial in Patients with IBS

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs. The company today announced it has received confirmation from the U.S. Food ...
TRYP:CC - Tryp Therapeutics Receives Confirmation From FDA To Proceed With Phase 2A Clinical Trial in Patients With IBS at Massachusetts General Hospital

KELOWNA, BC / ACCESSWIRE / July 13, 2023 / Tryp Therapeutics , Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, toda...

TRYP:CC - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Submits IND as Important Step in Advancing IBS Clinical Program

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs. The company today announced that it has submitted an Investigational New Dru...

TRYP:CC - Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients With IBS at Massachusetts General Hospital

KELOWNA, BC / ACCESSWIRE / May 24, 2023 / Tryp Therapeutics , Inc. (CSE:TRYP)(OTCQB:TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, tod...
TRYP:CC - Tryp Therapeutics discusses unique approach to psychedelic treatment study of binge eating

--News Direct-- Tryp Therapeutics CEO James Gilligan joins Natalie Stoberman from the Proactive studio to share how the company is developing psychedelic-assisted therapy in treating various disorders such as binge eating and IBS. Gilligan says Tryp Therapeutics is taking a unique app...

TRYP:CC - InvestorNewsBreaks - Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Closes on AUD $2.4M Oversubscribed Private Placement

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) , a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, has closed on a private placement of secured convertible debentures. According...

TRYP:CC - Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Secured Convertible Debentures for Gross Proceeds of AUD$2,400,000

KELOWNA, BC / ACCESSWIRE / April 27, 2023 / Tryp Therapeutics Inc. (" Tryp " or the " Company ") ( CSE:TRYP ), a clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs,is pleased to ...
Previous 10 Next 10